Department of Paediatric and Adolescent Oncology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom.
Pediatr Blood Cancer. 2010 Jul 1;54(7):983-9. doi: 10.1002/pbc.22364.
This prospective longitudinal single institution cohort study evaluated the natural history of and risk factors for chronic nephrotoxicity 10 years after ifosfamide treatment in childhood.
Twenty-five patients (16 males) treated with ifosfamide were investigated at end of treatment (End), 1 and 10 years later. Glomerular filtration rate (GFR), serum phosphate (PO4) and bicarbonate (HCO3) and renal tubular threshold for phosphate (Tmp/GFR) were measured, and total nephrotoxicity score (Ns) graded.
More patients had a low GFR at 1 (72%) and 10 (50%) years than at End (26%) (P = 0.006 for End vs. 1 year). Electrolyte supplementation requirements for tubular toxicity resolved by 10 years (0% vs. 32% at End and 24% at 1 year; both P < 0.05). At 10 years, 17% of patients had moderate overall nephrotoxicity and 13% clinically significant reduction of GFR (<60 ml/min/1.73 m2). Neither dose nor age at treatment predicted any measure of toxicity at 10 years or reduced GFR at any timepoint. Higher cumulative ifosfamide dose correlated with greater tubular and overall nephrotoxicity at End and/or 1 year (P < 0.05 for each of PO4, HCO3, Tmp/GFR, Ns), but age at treatment did not differ between patients with normal or abnormal results.
Although clinically significant tubular toxicity had resolved by 10 years, GFR was <60 ml/min/1.73 m2 in 13% of patients, raising concerns about very long-term glomerular function. Higher cumulative dose was associated with greater tubular and overall toxicity at End and 1 year, but not at 10 years. Age at treatment did not predict nephrotoxicity at any timepoint.
本前瞻性纵向单中心队列研究评估了儿童使用异环磷酰胺治疗 10 年后慢性肾毒性的自然史和危险因素。
对 25 例(男 16 例)接受异环磷酰胺治疗的患者进行了研究,分别在治疗结束时(End)、1 年和 10 年后进行检查。测量肾小球滤过率(GFR)、血清磷酸盐(PO4)和碳酸氢盐(HCO3)以及磷酸盐肾小管阈值(Tmp/GFR),并对总肾毒性评分(Ns)进行分级。
与治疗结束时(26%)相比,更多的患者在 1 年(72%)和 10 年(50%)时肾小球滤过率较低(P = 0.006,End 与 1 年比较)。肾小管毒性的电解质补充需求在 10 年内得到解决(End 时为 0%,1 年时为 32%,10 年时为 24%;均 P < 0.05)。10 年后,17%的患者有中度整体肾毒性,13%的患者肾小球滤过率显著降低(<60 ml/min/1.73 m2)。治疗时的剂量和年龄均不能预测 10 年后任何毒性指标或任何时间点的肾小球滤过率降低。更高的累积异环磷酰胺剂量与治疗结束时和/或 1 年时的肾小管和整体肾毒性更大相关(PO4、HCO3、Tmp/GFR、Ns 每个指标均 P < 0.05),但治疗时的年龄在正常和异常结果的患者之间没有差异。
尽管临床显著的肾小管毒性在 10 年内得到解决,但仍有 13%的患者肾小球滤过率<60 ml/min/1.73 m2,这引发了对长期肾小球功能的担忧。更高的累积剂量与治疗结束时和 1 年时的肾小管和整体毒性更大相关,但与 10 年时无关。治疗时的年龄不能预测任何时间点的肾毒性。